Invetech, a global leader in solving complex manufacturing and product development challenges in the advanced therapies and diagnostics markets, today announced a strategic collaboration with AiCella, a company focused on harnessing the power of artificial intelligence (AI) to optimize the development of cell therapy production processes and maximize patient response to treatment. This partnership brings together Invetech's deep domain expertise in End-to-End custom automation with AiCella's cutting-edge artificial intelligence platform to deliver smarter, faster, and more cost-effective solutions for the industry - accelerating innovation and improving outcomes across the cell therapy landscape.

"This collaboration is about more than just combining technologies—it's about solving some of the most persistent challenges in cell therapy production," said Andreas Knaack, President of Invetech. "By integrating AiCella's predictive AI models with our proven technology platforms, we aim to help therapy developers identify critical process parameters earlier, reduce manufacturing variability, and ultimately accelerate the path to scalable, patient-ready therapies."

"Our goal at AiCella is to uncover the hidden relationships between process inputs and patient outcomes—insights that traditional methods often miss," said Geoffrey Stephens, PhD, CEO and Founder of AiCella. "Through this collaboration with Invetech, we're embedding our AI models directly into the development and manufacturing lifecycle. This allows us to not only optimize process performance but also to generate data-driven hypotheses about which parameters most influence therapeutic efficacy—bringing us closer to truly personalized, responsive cell therapies."

Invetech and AiCella will both be participating in upcoming industry events and webinars throughout 2025, including Meeting on the Mesa in October, where both companies will exhibit their joint capabilities.